Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Papp

Showing results (131-140 of 460) with videos related to

Pageof 46
Sort By:
Journal of Drugs in Dermatology : JDD|November 9, 2012
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agentsKim A Papp, Bruce Strober, Matthias Augustin, et al.
Prostaglandins, Leukotrienes, and Medicine|April 1, 1984
Effect of pH on the gel filtration of prostaglandinsE R Hall, A Papp, K K Wu, et al.
Magyar Sebeszet|April 13, 2001
[Larynx-preserving pharyngoesophagectomy in the treatment of cancer of the pharyngoesophageal junction]O P Horváth, L Cseke, A Papp, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2012
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison studyK A Papp, R Kaufmann, D Thaçi, et al.
The British Journal of Dermatology|February 21, 2008
Beneficial effect of resin salve in treatment of severe pressure ulcers: a prospective, randomized and controlled multicentre trialA Sipponen, J J Jokinen, P Sipponen, et al.
Journal of Cutaneous Medicine and Surgery|March 22, 2007
Efalizumab for the treatment of psoriatic arthritisKim A Papp, Ivor Caro, Hoi M Leung, et al.
Drug Safety|July 19, 2008
Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trialTiffani Hamilton, Alan Menter, Ivor Caro, et al.
Journal of Drugs in Dermatology : JDD|February 18, 2004
Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasisAlan Menter, Mark Kosinski, Brian W Bresnahan, et al.
Journal of Pharmaceutical Sciences|September 1, 1984
Pharmacokinetics of mitomycin C in dogs: application of a high-performance liquid chromatographic assayR H Barbhaiya, E A Papp, D R Van Harken, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 11, 2017
Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL studyC-H Hong, K A Papp, K W Lophaven, et al.
Pageof 46

Showing results (131-140 of 460) with videos related to

Sort By:
Pageof 46
Journal of Drugs in Dermatology : JDD|November 9, 2012
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agentsKim A Papp, Bruce Strober, Matthias Augustin, et al.
Prostaglandins, Leukotrienes, and Medicine|April 1, 1984
Effect of pH on the gel filtration of prostaglandinsE R Hall, A Papp, K K Wu, et al.
Magyar Sebeszet|April 13, 2001
[Larynx-preserving pharyngoesophagectomy in the treatment of cancer of the pharyngoesophageal junction]O P Horváth, L Cseke, A Papp, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2012
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison studyK A Papp, R Kaufmann, D Thaçi, et al.
The British Journal of Dermatology|February 21, 2008
Beneficial effect of resin salve in treatment of severe pressure ulcers: a prospective, randomized and controlled multicentre trialA Sipponen, J J Jokinen, P Sipponen, et al.
Journal of Cutaneous Medicine and Surgery|March 22, 2007
Efalizumab for the treatment of psoriatic arthritisKim A Papp, Ivor Caro, Hoi M Leung, et al.
Drug Safety|July 19, 2008
Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trialTiffani Hamilton, Alan Menter, Ivor Caro, et al.
Journal of Drugs in Dermatology : JDD|February 18, 2004
Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasisAlan Menter, Mark Kosinski, Brian W Bresnahan, et al.
Journal of Pharmaceutical Sciences|September 1, 1984
Pharmacokinetics of mitomycin C in dogs: application of a high-performance liquid chromatographic assayR H Barbhaiya, E A Papp, D R Van Harken, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 11, 2017
Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL studyC-H Hong, K A Papp, K W Lophaven, et al.
Pageof 46